Author:
Zhao Xudong,Li Lei,Ma Xiuping,Li Yang,Gao Beibei,Luo Weifeng
Funder
the National Natural Science Foundation of China
Suzhou Science and Technology Plan Project
Publisher
Springer Science and Business Media LLC
Subject
Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology
Reference34 articles.
1. Abramsky O, Litvin Y (1978) Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson’s disease and schizophrenia. Perspect Biol Med 22(1):104–114
2. Adithya G, Mackie PM, Phan LT, Gámez TM, Habibeh K (2023) The complex role of inflammation and gliotransmitters in Parkinson’s disease. Neurobiol Dis 176:105940
3. Allison S, Gruber-Baldini AL, Rainer von Coelln F, Savitt JM, Reich SG, Armstrong MJ, Shulman LM (2021) Comparison of mini-mental state examination and montreal cognitive assessment ratings across levels of parkinson’s disease severity. J Parkinsons Dis. 11(4):1995–2003
4. Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Førland MG, Tysnes O-B, Larsen JP, Pedersen KF (2014) CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology 82(20):1784–1790
5. Björn S (2017) Interleukin 4-induced neuroprotection and regulation of microglia activation as a therapeutic approach in the MPTP model of Parkinson’s disease. Neural Regen Res 12(9):1433–1434